Study: NCT01458366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase 1: Given via IV at the following dose levels:~* Level 1: 70 mg/m2~* Level -1: 50 mg/m2~* Level 2: 90 mg/m2~* Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase 1: Given via IV at the following dose levels:~* Level 1: 70 mg/m2~* Level -1: 50 mg/m2~* Level 2: 90 mg/m2~* Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase 1: Given via IV at the following dose levels:~* Level 1: 70 mg/m2~* Level -1: 50 mg/m2~* Level 2: 90 mg/m2~* Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase 1: Given via IV at the following dose levels:~* Level 1: 70 mg/m2~* Level -1: 50 mg/m2~* Level 2: 90 mg/m2~* Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase 1: Given via IV at the following dose levels:~* Level 1: 70 mg/m2~* Level -1: 50 mg/m2~* Level 2: 90 mg/m2~* Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Phase II~* Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~* Cycles 2 and 3: 1000 mg via IV on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Phase II~* Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~* Cycles 2 and 3: 1000 mg via IV on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Phase II~* Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~* Cycles 2 and 3: 1000 mg via IV on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Phase II~* Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~* Cycles 2 and 3: 1000 mg via IV on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Phase II~* Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~* Cycles 2 and 3: 1000 mg via IV on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Phase II: AUC 5 via IV on Day 2 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Phase II: AUC 5 via IV on Day 2 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Phase II: AUC 5 via IV on Day 2 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Phase II: AUC 5 via IV on Day 2 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Phase II: AUC 5 via IV on Day 2 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant (STC)
Description: For potential transplant candidates:~* Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee~* Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant (STC)
Description: For potential transplant candidates:~* Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee~* Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant (STC)
Description: For potential transplant candidates:~* Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee~* Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant (STC)
Description: For potential transplant candidates:~* Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee~* Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant (STC)
Description: For potential transplant candidates:~* Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee~* Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee